Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations
Authors:
- 15 January 2021
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 186 (1) , 259-263
Abstract
Purpose The co-occurrence or double heterozygosity of pathogenic/likely pathogenic sequence variants (P/LPSVs) in major cancer susceptibility genes has rarely been reported. Such co-occurrence raises the issues of accurate genetic counseling, preferred recommended surveillance scheme, and the use of preimplantation genetic diagnosis (PGD). Methods A clinical report of an Ashkenazi Jewish (AJ) family with co occurrence of two PSVs in BRCA1 and TP53 and a literature search. Results In an AJ family with a substantial history of cancer limited to the maternal side, two siblings co-harbored TP53 (c.733C>A; p.G245S) and the predominant 5266dup BRCA1 mutation, originating from the mother and the father, respectively. PGD is ongoing. Four families were thus far reported as double heterozygotes for both BRCA1/BRCA2 and TP53. Based on the limited available data, it seems that the phenotype in double PSV heterozygotes is not more severe than in single PSV carrier in either gene. Conclusions This family highlights the need to genotype both parents, especially in populations with founder mutations, when a BRCA1 mutation is detected in an offspring, regardless of family history. The combination of mutations in these two genes presents a challenge for PGD since both genes are located on chromosome 17.Keywords
This publication has 18 references indexed in Scilit:
- Identification of a breast cancer family double heterozygote for RAD51C and BRCA2 gene mutationsFamilial Cancer, 2014
- Double heterozygosity for germline mutations in BRCA1 and p53 in a woman with early onset breast cancerBreast Cancer Research and Treatment, 2014
- Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortiumEuropean Journal of Cancer, 2014
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- A case of endometrial cancer in the context of a BRCA2 mutation and double heterozygosity for Lynch syndromeGynecologic Oncology Case Reports, 2012
- Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancerDifferentiation, 2009
- BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanomaFamilial Cancer, 2007
- Founder mutations in early-onset, familial and bilateral breast cancer patients from RussiaFamilial Cancer, 2007
- Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma familiesEuropean Journal of Cancer, 2007
- Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2Nature Genetics, 1996